Sr. Director CVM PAClinical Pharmacology and Pharmacometrics, Johnson and Johnson Innovative MedicineRaritan, New Jersey, United States
OC 66.2 - Characterizing the Relationship between Milvexian Exposure, Efficacy, and Safety in Total Knee Replacement Patients to Support Milvexian Phase 3 Dose Selection.
Tuesday, June 25, 202415:00 – 15:15 ICT
OC 66.3 - A model-based meta-analysis leveraging total knee replacement (TKR) data for selection of the milvexian dose for a phase 3 study in participants with atrial fibrillation.
Tuesday, June 25, 202415:15 – 15:30 ICT
